Takeda Pharmaceutical Company Limited

Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Xinthera, Inc.

Alumis Inc.

Novartis Ag

Sichuan Haisco Pharmaceutical Co., Ltd.

Fronthera U.S. Pharmaceuticals LLC

Xizang Haisco Pharmaceutical Co., Ltd.

Other

Takeda San Diego, Inc.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Chengdu Easton Biopharmaceuticals Co., Ltd

Takeda Pharmaceutical Company Limied

Triad Liquidating Company, LLC

Qing Dong

Stephen W Kaldor

Bohan Jin

Piaoyang Sun

Gene Hung

Michael Brennan Wallace

Nicholas Scorah

Robert L Hoffman

Lynnie Lin Trzoss

Jeffrey Alan Stafford

Jiong Lan

Joseph Robert Pinchman

Bheema Rao Paraselli

Hejun Lu

Fei Li

Toufike Kanouni

Zhe Nie

Christopher Ronald Smith

Benjamin Jones

Yasuyoshi Arikawa

Betty Lam

Yang Wayne Wang

Zhiyuan Zhang

John David Lawson

Qiyue Hu

Fanglong Yang

Edcon Chang

Xuejun Zhang

Jianqiang Wang

Hongjian Jiang

David J Hosfield

Tony Gibson

Yaoping Zhu

Haitao Yang

Xing Liu

Wei He

Bin Wang

Jason W Brown

Ling L Zhang

Maurizio Pellecchia

Peng Cho Tang

Fabrice Pierre

Yang Liu

Junhu Zhang

Guoqing Cao

Pengyu Yang

Yan Liu

Porino Jinjo Va

Victoria Feher

Masashi Takahashi

Bin Gui

Bonian Liu

Xiaotao Li

Yao Li

Hongbo Fei

Wangyang Tu

Fangfang Jin

Hengyuan Lang

Daniel S Sem

Jianbiao Peng

Ying Wang

Jijun Yuan

Guangyuan Shen

Min Sang Lee

Guodong Cen

Mark E Adams

Naoki Tomita

Haowei Wang

Limin Zhang

Jiang Fan

Wei Peng

Dongliang Guan

Guoji Xu

Haitang Zhang

Jiangtao Chi

Xianchang Gong

Long Huang

Yongzhe Xiang

Lei Chen

Mark Kelly

Jianguo Li

Chunfei Wang

Chunzhou Han

Jihui Han

Steven W Kaldor

Hasanthi Wijesekera

Toufiko Kanounl

Venkat Bollu

Lynnie Trzoss

Jianjing Jia

Qiangqiang Liu

Xianbo Liu

Chunyan Gu

Feng Zhou

Christopher Smith

Lam Betty

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Substituted pyridines as PARP1 inhibitors

Described herein are modulators of TNF alpha activity and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TNF alpha-mediated disorders or diseases.

Modulators of TNF alpha activity and uses thereof

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

PARP1 inhibitors and uses thereof

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

Thyroid hormone receptor agonists and uses thereof

Described herein are compounds, for example, substituted 1,2,4-triazoles, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as TYK2 inhibitors

Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Pyridinone MK2 inhibitors and uses thereof

Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors

Described herein are compounds, for example, substituted pyridazines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted pyridazines as TYK2 inhibitors

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer and are of Formula (Ip):

Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

MK2 inhibitors and uses thereof

Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer and are of Formula I(b)

Azetidine and pyrrolidine PARP1 inhibitors and uses thereof

Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TY-K2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Growing community of inventors

San Diego, CA, United States of America

Qing Dong